Aghayan Hamid Reza, Payab Moloud, Mohamadi-Jahani Fereshteh, Aghayan Seyed Sajjad, Larijani Bagher, Arjmand Babak
Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Obesity and Eating Habits Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Methods Mol Biol. 2021;2286:213-225. doi: 10.1007/7651_2020_282.
Mesenchymal stem cells are one of the most attractive sources for stem cell research and therapy. Their safety and efficacy have been demonstrated in many clinical trials. Because of their low immunogenicity and immunomodulatory properties, allogenic MSCs have been transplanted in different clinical studies. MSCs could be in different adult- and fetal-derived tissues including pregnancy products. Placenta-derived mesenchymal stem cells (PLMSCs) that can be harvested without using any invasive procedures from a discarding tissue are one of the important types of mesenchymal stem cells for therapeutic applications. Stem cell manufacturing for therapeutic applications should be in compliance with the basic principles of good manufacturing practice (GMP). Herein, the current chapter is to describe GMP-compliant production of human PLMSCs, which are suitable for clinical applications.
间充质干细胞是干细胞研究和治疗中最具吸引力的来源之一。它们的安全性和有效性已在许多临床试验中得到证实。由于其低免疫原性和免疫调节特性,同种异体间充质干细胞已被用于不同的临床研究。间充质干细胞可存在于不同的成人和胎儿来源的组织中,包括妊娠产物。胎盘来源的间充质干细胞(PLMSCs)可以从废弃组织中通过非侵入性程序获取,是用于治疗应用的重要间充质干细胞类型之一。用于治疗应用的干细胞生产应符合良好生产规范(GMP)的基本原则。在此,本章将描述符合GMP标准的人PLMSCs的生产,这些细胞适用于临床应用。